Oral vs Injectable AAS17α-Alkylated Orals vs Ester-Based Injectables — Research Guide by QSC Peptides

17α-Alkylation — Oral Bioavailability Mechanism

All oral AAS in the QSC Peptides catalog are C17α-alkylated — they carry a methyl group at carbon-17 that sterically blocks hepatic 17β-hydroxysteroid dehydrogenase (17β-HSD) from oxidizing the 17β-hydroxyl to an inactive 17-ketone. This protection enables GI absorption without hepatic first-pass inactivation. The tradeoff is direct hepatic exposure during portal circulation, contributing to 17α-AA hepatotoxicity.

Injectable Ester Pharmacokinetics

Injectable AAS are typically esterified at the 17β-hydroxyl position with fatty acids of varying carbon chain length. After depot injection into muscle, ester hydrolases cleave the ester bond over time, releasing free testosterone (or other AAS base). Release rate is inversely proportional to ester carbon chain length — Propionate (C3) releases in ~2 days; Decanoate (C10) releases over ~15 days.

Research Design Implications

• Acute studies: Oral AAS (short t½) enable rapid on/off protocols — ideal for studying immediate AR activation, gene expression changes, or recovery kinetics
• Chronic studies: Long-ester injectables (Test E, DECA) maintain stable blood levels ideal for chronic exposure models, steady-state pharmacokinetics, and long-duration endpoint studies
• Hepatotoxicity research: C17α-AA orals (Dianabol, Anadrol, Anavar, Winstrol) provide the model system; injectables serve as controls
• Washout design: Short-acting orals or short-ester injectables (Tren Ace, Test P) enable rapid clearance between treatment phases